MT Newswires10d agobullish
UBS Adjusts Price Target on Biogen to $300 From $270, Keeps Buy RatingNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3126last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
MT Newswires10d agobullish
RBC Raises Price Target on Biogen to $272 From $256, Keeps Outperform RatingInvesting.com87d agobullish
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuationInvesting.com118d agobullish
Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key dataBarrons.com118d agobullish
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details